Biomarin Pharmaceutical Inc (BMRN) 129.13 $BMRN
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), ESPR: 92.04 (+1.39), ACAD: 33.35 (+1.39), BMRN: 129.13 (+0.35), ICEL: 16.42 (+8.48), UNH: 121.00 (+2.99), HZNP: 25.77 (+3.96), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Critical Alerts For GoPro, BioMarin Pharmaceutical, Altera, CVS Caremark and Halliburton Released By InvestorsObserver
PR Newswire - Mon Mar 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, BMRN, ALTR, CVS and HAL.
GPRO: 43.58 (+0.88), BMRN: 129.13 (+0.35), ALTR: 42.82 (-1.57), HAL: 43.82 (+0.56), CVS: 103.83 (+1.33)
BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
GlobeNewswire - Mon Mar 30, 8:09AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan(R) (sapropterin dihydrochloride)at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. The sub-analysis included 86 subjects 8 to 17 years of age with PKU who were randomized to blinded treatment with Kuvan (N = 43) or placebo (N = 43) for 13 weeks, after which all individuals received open label Kuvan for an additional 13 weeks.
BMRN: 129.13 (+0.35)
BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose nearly 12% on the day.
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
BioMarin Pharmaceuticals
at Investor's Business Daily - Fri Mar 27, 5:54PM CDT
BioMarin Pharmaceuticals (BMRN) climbed 11.5% to 128.78 after Deutsche Bank suggested in a report Fri. the maker of drugs for rare diseases may be a takeover target as a consolidation wave sweeps drugmakers. Reports also said Ireland's Shire (SHPG)...
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
BioMarin Pharma Hits All-Time High
at Investor's Business Daily - Fri Mar 27, 5:40PM CDT
BioMarin Pharmaceutical (BMRN) stock rose 11.5% to an all-time high Friday on heavy volume as speculation builds that the company could be the next big biotech takeout. The stock jumped as investment bank UBS raised its price target on BioMarin...
BMRN: 129.13 (+0.35), GSK: 47.20 (+0.18)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 11.45%
Comtex SmarTrend(R) - Fri Mar 27, 3:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $123.05 to a high of $133.54. Yesterday, the shares gained 11.4%, which took the trading range above the 3-day high of $126.00 on volume of 6.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 129.13 (+0.35)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), MON: 113.38 (+0.65), IBB: 351.32 (+3.86), SOXX: 95.09 (+1.20), NXPI: 102.43 (+2.51), KMX: 69.22 (+2.53), AYI: 172.57 (+4.57), AA: 12.96 (+0.26), TXN: 58.00 (+1.24), ADI: 64.81 (+5.97), ALXN: 180.26 (-0.33), AVGO: 130.55 (+2.34), REGN: 459.78 (+5.28)
BioMarin Pharmaceutical (BMRN) Stock Gains Today on Merger Rumors
at The Street - Fri Mar 27, 2:44PM CDT
BioMarin (BMRN) shares are spiking today on an analyst note suggesting that the company is close to a merger with Shire (SHPG).
BMRN: 129.13 (+0.35)
Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech
at The Street - Fri Mar 27, 2:11PM CDT
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), GME: 37.69 (-0.67), OLN: 32.41 (+1.41), BBRY: 8.80 (-0.66), IBB: 351.32 (+3.86), HPQ: 31.57 (+0.08), YHOO: 44.95 (-0.15), ALXN: 180.26 (-0.33), DOW: 48.68 (+0.92), REGN: 459.78 (+5.28)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:45AM CDT
DHRM: 2.70 (-0.10), GGB: 3.19 (+0.13), BMRN: 129.13 (+0.35), OLN: 32.41 (+1.41), HCHC: 11.35 (-0.58), APDN: 2.70 (unch), ZQK: 1.91 (+0.01), OXM: 72.16 (+1.36), ROLL: 75.53 (-0.05), GVP: 1.56 (-0.04), MOLG: 2.23 (-0.11), CCIH: 9.92 (-0.38), GBSN: 2.44 (-0.29), EVAR: 4.06 (+0.06), LIME: 3.40 (-0.16), CALA: 16.42 (-1.03), OHRP: 2.81 (+0.07), INPH: 1.47 (-0.27), CARV: 5.01 (-0.54), GNI: 8.38 (-0.65)
Why BioMarin Pharmaceutical Inc. Stock Is Surging Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 27, 10:16AM CDT
What's Happening: Shares of the orphan drug specialist BioMarin Pharmaceuticals rose by over 12% today on heavy volume after a rumor broke that the company could be the next big takeover target. While there are no credible sources backing this...
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:13AM CDT
OREX: 7.75 (+0.21), BMRN: 129.13 (+0.35), CPF: 23.05 (+0.07), MVIS: 3.52 (-0.02), OLN: 32.41 (+1.41), APDN: 2.70 (unch), BBRY: 8.80 (-0.66), OHRP: 2.81 (+0.07), LIVE: 3.18 (-0.06)
BioMarin Pharma up 10% on takeover speculation
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:34AM CDT
BMRN: 129.13 (+0.35)
Pharmacyclics, BioMarin, And Incyte: A Quick Screen
William Meyers - at Seeking Alpha - Thu Mar 26, 4:30PM CDT
PCYC: 256.43 (-0.12), BMRN: 129.13 (+0.35), INCY: 94.19 (-0.17), IBB: 351.32 (+3.86)
Biotech Stock Selloff: Is It Justified?
at Investor's Business Daily - Thu Mar 26, 11:12AM CDT
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray's Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead...
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), KITE: 59.98 (+0.20), GILD: 100.69 (-0.31), ALXN: 180.26 (-0.33), JUNO: 60.66 (+4.06), CELG: 120.02 (+1.34)
29.3% Return Seen to Date on SmarTrend BioMarin Pharmaceutical Call (BMRN)
Comtex SmarTrend(R) - Tue Mar 24, 9:23AM CDT
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on January 8th, 2015 at $95.60. In approximately 3 months, BioMarin Pharmaceutical has returned 29.31% as of today's recent price of $123.63.
BMRN: 129.13 (+0.35)
After Yesterday's Decline of 1.24%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 23, 4:28PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $121.45 to a high of $125.25. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.85 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 129.13 (+0.35)
Jim Cramer Digs Into Dozens of Charts, Finds 7 Pillars of Health Care Strength
at The Street - Mon Mar 23, 1:18PM CDT
Investors can handily beat the average by developing a portfolio of health care companies that try to service the colossus that is the American medical system.
BIIB: 431.62 (+1.75), BMRN: 129.13 (+0.35), ISIS: 64.81 (+1.44), ALXN: 180.26 (-0.33), AMGN: 164.30 (+1.71)
Technical Coverage on Biotech Stocks -- Cytori Therapeutics, Oncolytics Biotech, BioMarin Pharma, Aeterna Zentaris, and Immunomedics
PR Newswire - Thu Mar 19, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
IMMU: 3.89 (+0.18), BMRN: 129.13 (+0.35), ONCY: 0.77 (unch), CYTX: 1.20 (+0.01), AEZS: 0.53 (unch)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), ESPR: 92.04 (+1.39), ACAD: 33.35 (+1.39), BMRN: 129.13 (+0.35), ICEL: 16.42 (+8.48), UNH: 121.00 (+2.99), HZNP: 25.77 (+3.96), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Critical Alerts For GoPro, BioMarin Pharmaceutical, Altera, CVS Caremark and Halliburton Released By InvestorsObserver
PR Newswire - Mon Mar 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, BMRN, ALTR, CVS and HAL.
GPRO: 43.58 (+0.88), BMRN: 129.13 (+0.35), ALTR: 42.82 (-1.57), HAL: 43.82 (+0.56), CVS: 103.83 (+1.33)
BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
GlobeNewswire - Mon Mar 30, 8:09AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan(R) (sapropterin dihydrochloride)at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. The sub-analysis included 86 subjects 8 to 17 years of age with PKU who were randomized to blinded treatment with Kuvan (N = 43) or placebo (N = 43) for 13 weeks, after which all individuals received open label Kuvan for an additional 13 weeks.
BMRN: 129.13 (+0.35)
BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose nearly 12% on the day.
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
BioMarin Pharmaceuticals
at Investor's Business Daily - Fri Mar 27, 5:54PM CDT
BioMarin Pharmaceuticals (BMRN) climbed 11.5% to 128.78 after Deutsche Bank suggested in a report Fri. the maker of drugs for rare diseases may be a takeover target as a consolidation wave sweeps drugmakers. Reports also said Ireland's Shire (SHPG)...
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
BioMarin Pharma Hits All-Time High
at Investor's Business Daily - Fri Mar 27, 5:40PM CDT
BioMarin Pharmaceutical (BMRN) stock rose 11.5% to an all-time high Friday on heavy volume as speculation builds that the company could be the next big biotech takeout. The stock jumped as investment bank UBS raised its price target on BioMarin...
BMRN: 129.13 (+0.35), GSK: 47.20 (+0.18)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 11.45%
Comtex SmarTrend(R) - Fri Mar 27, 3:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $123.05 to a high of $133.54. Yesterday, the shares gained 11.4%, which took the trading range above the 3-day high of $126.00 on volume of 6.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 129.13 (+0.35)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), MON: 113.38 (+0.65), IBB: 351.32 (+3.86), SOXX: 95.09 (+1.20), NXPI: 102.43 (+2.51), KMX: 69.22 (+2.53), AYI: 172.57 (+4.57), AA: 12.96 (+0.26), TXN: 58.00 (+1.24), ADI: 64.81 (+5.97), ALXN: 180.26 (-0.33), AVGO: 130.55 (+2.34), REGN: 459.78 (+5.28)
BioMarin Pharmaceutical (BMRN) Stock Gains Today on Merger Rumors
at The Street - Fri Mar 27, 2:44PM CDT
BioMarin (BMRN) shares are spiking today on an analyst note suggesting that the company is close to a merger with Shire (SHPG).
BMRN: 129.13 (+0.35)
Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech
at The Street - Fri Mar 27, 2:11PM CDT
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), GME: 37.69 (-0.67), OLN: 32.41 (+1.41), BBRY: 8.80 (-0.66), IBB: 351.32 (+3.86), HPQ: 31.57 (+0.08), YHOO: 44.95 (-0.15), ALXN: 180.26 (-0.33), DOW: 48.68 (+0.92), REGN: 459.78 (+5.28)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:45AM CDT
DHRM: 2.70 (-0.10), GGB: 3.19 (+0.13), BMRN: 129.13 (+0.35), OLN: 32.41 (+1.41), HCHC: 11.35 (-0.58), APDN: 2.70 (unch), ZQK: 1.91 (+0.01), OXM: 72.16 (+1.36), ROLL: 75.53 (-0.05), GVP: 1.56 (-0.04), MOLG: 2.23 (-0.11), CCIH: 9.92 (-0.38), GBSN: 2.44 (-0.29), EVAR: 4.06 (+0.06), LIME: 3.40 (-0.16), CALA: 16.42 (-1.03), OHRP: 2.81 (+0.07), INPH: 1.47 (-0.27), CARV: 5.01 (-0.54), GNI: 8.38 (-0.65)
Why BioMarin Pharmaceutical Inc. Stock Is Surging Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 27, 10:16AM CDT
What's Happening: Shares of the orphan drug specialist BioMarin Pharmaceuticals rose by over 12% today on heavy volume after a rumor broke that the company could be the next big takeover target. While there are no credible sources backing this...
BMRN: 129.13 (+0.35), SHPG: 241.98 (+1.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:13AM CDT
OREX: 7.75 (+0.21), BMRN: 129.13 (+0.35), CPF: 23.05 (+0.07), MVIS: 3.52 (-0.02), OLN: 32.41 (+1.41), APDN: 2.70 (unch), BBRY: 8.80 (-0.66), OHRP: 2.81 (+0.07), LIVE: 3.18 (-0.06)
BioMarin Pharma up 10% on takeover speculation
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:34AM CDT
BMRN: 129.13 (+0.35)
Pharmacyclics, BioMarin, And Incyte: A Quick Screen
William Meyers - at Seeking Alpha - Thu Mar 26, 4:30PM CDT
PCYC: 256.43 (-0.12), BMRN: 129.13 (+0.35), INCY: 94.19 (-0.17), IBB: 351.32 (+3.86)
Biotech Stock Selloff: Is It Justified?
at Investor's Business Daily - Thu Mar 26, 11:12AM CDT
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray's Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead...
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), KITE: 59.98 (+0.20), GILD: 100.69 (-0.31), ALXN: 180.26 (-0.33), JUNO: 60.66 (+4.06), CELG: 120.02 (+1.34)
29.3% Return Seen to Date on SmarTrend BioMarin Pharmaceutical Call (BMRN)
Comtex SmarTrend(R) - Tue Mar 24, 9:23AM CDT
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on January 8th, 2015 at $95.60. In approximately 3 months, BioMarin Pharmaceutical has returned 29.31% as of today's recent price of $123.63.
BMRN: 129.13 (+0.35)
After Yesterday's Decline of 1.24%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 23, 4:28PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $121.45 to a high of $125.25. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.85 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 129.13 (+0.35)
Jim Cramer Digs Into Dozens of Charts, Finds 7 Pillars of Health Care Strength
at The Street - Mon Mar 23, 1:18PM CDT
Investors can handily beat the average by developing a portfolio of health care companies that try to service the colossus that is the American medical system.
BIIB: 431.62 (+1.75), BMRN: 129.13 (+0.35), ISIS: 64.81 (+1.44), ALXN: 180.26 (-0.33), AMGN: 164.30 (+1.71)
Technical Coverage on Biotech Stocks -- Cytori Therapeutics, Oncolytics Biotech, BioMarin Pharma, Aeterna Zentaris, and Immunomedics
PR Newswire - Thu Mar 19, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
IMMU: 3.89 (+0.18), BMRN: 129.13 (+0.35), ONCY: 0.77 (unch), CYTX: 1.20 (+0.01), AEZS: 0.53 (unch)
